AstraZeneca PLC (AZN) Stock Price & How to Invest

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

The mid-2026 picture combines strong momentum with clear overhangs. Oncology sales grew double digits, Enhertu and Imfinzi kept climbing, and the company announced a $50 billion US manufacturing and R&D investment, anchored by a large drug-substance plant in Virginia, partly to align with US pricing and tariff pressure. At the same time, AstraZeneca moved its US listing from Nasdaq ADSs to a direct NYSE listing (effective late January 2026) to harmonize its global share structure. Two overhangs matter most: a patent cliff around 2032, when Tagrisso, Imfinzi and Calquence begin losing exclusivity (a headwind analysts size above $20 billion), and a China compliance case in which its former China head was indicted, alongside first generics reaching Farxiga in 2026.

The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and as a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision.

10 analysts publish price targets on AZN, averaging $213.69 against a $169.64 price as of August 2026, or +26.0%. The published targets run from $184.00 to $240.00, a narrow spread, and the ratings split 8 buy, 2 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AZN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on AstraZeneca PLC. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Oncology franchise and the $80 billion ambition. Oncology is AstraZeneca's largest and fastest-growing area, with Tagrisso, Imfinzi, Calquence, Lynparza and the Daiichi Sankyo-partnered Enhertu all contributing. The most optimistic published target, $240.00, assumes this works close to its best case.

The case against. The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. The most pessimistic target, $184.00, is roughly what AZN is worth if this bites instead.

Read the full bull and bear case on AZN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AstraZeneca PLC's investor relations page or your broker.

• Revenue (TTM): Around $60 billion; 2025 total revenue was about $58.7 billion, up roughly 9%, with Q1 2026 up about 8% at constant currency
• Growth drivers: Oncology (Tagrisso, Imfinzi, Calquence, Enhertu, Lynparza), rare disease (Ultomiris, Soliris) and metabolic launches; company ambition of $80 billion revenue by 2030
• Margins/profitability: Solidly profitable large-cap pharma; heavy, sustained R&D spending funds the pipeline that the 2030 target depends on
• Dividend: Pays a regular dividend; recent yield roughly 2%, modest for the sector but backed by large, growing cash flows
• Market cap: Very large, in the roughly $260 billion to $300 billion range depending on the day; among the biggest global pharma companies
• Analyst view: Generally constructive on the oncology and pipeline story, but weighing the post-2032 patent cliff and China overhang; views vary widely

Figures are approximate and tied to the asOf date; confirm live numbers before acting. AstraZeneca trades as a growth-oriented large-cap pharma, so its valuation reflects confidence in the pipeline delivering on the $80 billion 2030 goal more than any single current metric. A patent cliff early next decade means today's revenue base is not guaranteed to persist, so how you weigh future launches matters more than trailing multiples.

If you want AZN exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to AZN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AZN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (IEFA, EFA, VXUS), which spreads the position across many companies. Or build it into a focused thematic portfolio, so AZN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AZN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AstraZeneca is a large, diversified biopharma with fast-growing oncology and rare-disease franchises and a clear $80 billion 2030 revenue ambition, set against a real patent cliff early next decade. The question is whether the pipeline can outrun the loss of exclusivity, not whether the base business works.

Whether AZN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AZN a buy or a sell?, and where the stock could go from here in the AZN stock forecast.

For income investors, whether AZN pays a dividend and how the payout looks is covered in does AZN pay a dividend? And to weigh AZN against a peer, read the full side-by-side comparisons: AZN vs BMY and AZN vs PFE.